Nov 17 (Reuters) – The US FDA on Tuesday granted accelerated approval to GSK’s therapy for a rare form of advanced lung cancer in patients whose disease has worsened on existing drugs, marking another regulatory win for the company’s historic $10.6 billion acquisition of Nuvalent.
CEO Luke Miels is spearheading GSK’s return to oncology, a business it exited a decade ago, and its Nuvalent acquisition has been the company’s most aggressive move so far in that direction.
The therapy, neladalkib, with the brand name Nelkarmi, is approved for patients with a type of non-small cell lung cancer whose disease has progressed after treatment with ALK tyrosine kinase inhibitors, a class of targeted drugs that block an abnormal protein driving tumor growth.
The approval offers a new option to patients who have exhausted existing targeted treatments, for whom chemotherapy has often been the main remaining choice.
Neladalkib was one of two late-stage lung cancer drugs GSK gained through the acquisition, which was completed in July. The other, Jideytro, won FDA approval the same month.
(Reporting by Kamal Choudhury and Unnamalai L in Bengaluru, Bhanvi Satija in London; Editing by Shailesh Kuber and Maju Samuel)
Brought to you by www.srnnews.com
SRN News — View the original story at SRNNews.com.
